Iruplinalkib in Patients with ALK-Positive CrizotinibResistant NSCLC: Updated Efficacy and Safety Data from a Phase 2 Trial

被引：0

作者：

Shi, Y. ^{[1
]}

Chen, J. ^{[2
]}

Zhang, H. ^{[3
]}

Zhang, Z. ^{[4
]}

Zhang, Y. ^{[5
,24
]}

Wang, Z. ^{[6
]}

Zhang, S. ^{[7
]}

Zhao, J. ^{[8
,16
]}

Liu, C. ^{[9
]}

Wang, X. ^{[10
]}

Zhao, Y. ^{[11
,12
]}

Hu, C. ^{[4
]}

Yang, L. ^{[13
]}

Hao, X. ^{[1
]}

Wang, L. ^{[1
]}

Liu, Y. ^{[14
]}

Yu, Y. ^{[15
]}

Zhao, J. ^{[8
,16
]}

Wang, M. ^{[17
]}

Zhang, L. ^{[18
]}

Sun, S. ^{[19
]}

Hu, Y. ^{[20
]}

Gu, K. ^{[21
]}

Hang, X. ^{[22
]}

Shan, J. ^{[22
,23
]}

Zhang, Y. ^{[5
,24
]}

Tan, B. ^{[25
]}

Yang, W. ^{[26
]}

Yang, R. ^{[27
]}

Si, M. ^{[28
]}

Li, H. ^{[28
]}

Kang, X. ^{[28
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Nat Canc Ctr, Natl Clin Res Ctr Cancer, Canc Hosp, Beijing, Peoples R China

[2] Hunan Tumor Hosp, Changsha, Peoples R China

[3] Air Force Med Univ, Affiliated Hosp 2, Xian, Peoples R China

[4] Anhui Prov Canc Hosp, Hefei, Peoples R China

[5] Zhejiang Canc Hosp, Hangzhou, Peoples R China

[6] Shandong Prov Inst Canc Prevent & Treatment, Jinan, Peoples R China

[7] Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China

[8] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China

[9] Xingjiang Med Univ, Affiliated Tumour Hosp, Urumqi, Peoples R China

[10] Shandong Univ, Qilu Hosp, Jinan, Peoples R China

[11] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[12] Henan Canc Hosp, Zhengzhou, Peoples R China

[13] Gansu Prov Canc Hosp, Lanzhou, Peoples R China

[14] China Med Univ, Hosp 1, Shenyang, Peoples R China

[15] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China

[16] Peking Univ, Canc Hosp, Beijing, Peoples R China

[17] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing, Peoples R China

[18] Yantai Yuhuangding Hosp, Yantai, Peoples R China

[19] Cent Hosp, Hubei Canc Hosp, Wuhan, Peoples R China

[20] Hubei Canc Hosp, Wuhan, Peoples R China

[21] Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China

[22] Jiangnan Univ, Affiliated Hosp, Wuxi, Jiangsu, Peoples R China

[23] Army Med Ctr PLA, Chongqing, Peoples R China

[24] Nanjing Chest Hosp, Nanjing, Peoples R China

[25] North Sichuan Med Coll, Affiliated Hosp, Nanchong, Peoples R China

[26] Shanxi Prov Canc Hosp, Taiyuan, Peoples R China

[27] Yunnan Canc Hosp, Kunming, Yunnan, Peoples R China

[28] Qilu Pharmaceut Co Ltd, Jinan, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

Iruplinalkib; Non-small cell lung cancer; Crizotinib-resistant;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.12B.07

引用

页码：S203 / S203

页数：1

共 50 条

[1] Lorlatinib for Previously Treated ALK-positive Advanced NSCLC: Updated Efficacy and Safety Data from a Phase 2 Study in China
Lu, S.
Zhou, Q.
Liu, X.
He, S.
Zhao, H.
Li, H.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S121 - S121
[2] Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
Lu, S.
Zhou, Q.
Liu, X.
Du, Y.
Fan, Y.
Cheng, Y.
Fang, J.
Lu, Y.
Huang, C.
Zhou, J.
Song, Y.
Wang, K.
Pan, H.
Yang, N.
Li, J.
Chen, G.
Chang, J.
Cui, J.
Liu, Z.
Bai, C.
Zhang, H.
Thurm, H.
Peltz, G.
Li, H.
Zhao, H.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1088 - S1089
[3] A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
Dikopf, Alana
Wood, Kevin
Salgia, Ravi
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (03) : 485 - 493
[4] EFFICACY AND TOXICITY OF CRIZOTINIB FOR PATIENTS WITH ALK-POSITIVE ADVANCED NSCLC
Asao, T.
Honma, Y.
Suina, K.
Muraki, K.
Shukuya, T.
Ohashi, R.
Koyama, R.
Shimada, N.
Sakuraba, S.
Takahashi, K.
ANNALS OF ONCOLOGY, 2013, 24
[5] Crizotinib Efficacy in ALK-Positive Advanced NSCLC Chinese Patients
Cui, Shaohua
Zhao, Yizhuo
Gu, Aiqin
Ge, Xiaoxiao
Song, Yanyan
Zhang, Wei
Lou, Yuqing
Dong, Lili
Han, Baohui
Jiang, Liyan
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S412 - S412
[6] Efficacy and safety of crizotinib for treatment of ALK-positive NSCLC: a meta-analysis
Du, Xing
Zheng, Xiaoli
Wang, Pengcheng
Wang, Yi
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (11): : 11763 - 11771
[7] Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of Alectinib in ALK plus NSCLC
Shaw, Alice
West, Howard
Socinski, Mark A.
Ou, Ignatius
Gandhi, Leena
Gadgeel, Shirish
Belani, Chandra P.
Shirai, Keisuke
Bazhenova, Lyudmila
Santos, Edgardo
Riely, Gregory J.
Chiappori, Alberto
Cetnar, Jeremy
Mekhail, Tarek
Chao, Bo
Borghaei, Hossein
Gold, Kathryn A.
Johannsdottir, Hrefna
Ruf, Thorsten
Boisserie, Frederic
Henschel, Volkmar
Zeaiter, Ali
Camidge, Ross
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S237 - S238
[8] Crizotinib Versus Chemotherapy On ALK-positive NSCLC: A Systematic Review of Efficacy and Safety
Wang, Mingxia
Wang, Guanqi
Ma, Haiyan
Shan, Baoen
CURRENT CANCER DRUG TARGETS, 2019, 19 (01) : 41 - 49
[9] Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer
Camidge, D. Ross
Gadgeel, Shirish
Ou, Sai-Hong
Gandhi, Leena
Riely, Gregory
Cetnar, Jeremy
West, Howard
Socinski, Mark
Chiappori, Alberto
Mekhail, Tarek
Chao, Bo
Borghaei, Hossein
Gold, Kathryn
Bordogna, Walter
Balas, Bogdana
Noe, Johannes
Golding, Sophie
Zeaiter, Ali
Shaw, Alice
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S378 - S378
[10] A PHASE I/II STUDY OF ALK INHIBITOR CH5424802 IN PATIENTS WITH ALK-POSITIVE NSCLC; SAFETY AND EFFICACY INTERIM RESULTS OF THE PHASE II PORTION
Nishio, M.
Kiura, K.
Nakagawa, K.
Seto, T.
Inoue, A.
Maemondo, M.
Hida, T.
Harada, M.
Yoshioka, H.
Tamura, T.
ANNALS OF ONCOLOGY, 2012, 23 : 153 - 153

← 1 2 3 4 5 →